ClinicalTrials.gg
CompletedNCT03028142Updated Feb 27, 2019Results posted

The Effects of RPL554 in Addition to Tiotropium in COPD Patients

A Phase 2 interventional study of 1.5 mg RPL554 plus tiotropium and 6 mg RPL554 plus tiotropium in Chronic Obstructive Pulmonary Disease Moderate, sponsored by Verona Pharma plc. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-02-27.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.

Enrollment
13th of 15
30 · median 79
Started
2017
with 1 other
Phase 2
8 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
9 of 15
Verona Pharma plc

Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 13th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 3rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ensifentrine

ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a phase II, randomised, double blind, placebo controlled, complete block, three way crossover study to investigate treatment with nebulised RPL554 and tiotropium together in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The purpose of this study is to assess the bronchodilator effect (opening of the airways) of RPL554 when used in combination with a long acting anti-muscarinic receptor antagonist (tiotropium) whilst dosing the RPL554 to steady state blood levels. It is planned to randomise up to 30 patients to have 24 evaluable patients at one study centre. In each treatment period, patients will receive an open label dose of tiotropium from a dry power inhaler (DPI) followed immediately by a double blind dose of either RPL554 6mg, 1.5mg or placebo (depending on treatment sequence) from a nebuliser in the morning on Day 1, Day 2 and Day 3. The dose of RPL554 or placebo will be repeated in the evening on Day 1 and Day 2; there will not be an evening dose on Day 3.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease Moderate
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign an document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
  2. Male or female aged between 40 and 75 years inclusive, at the time of informed consent.
  3. If male: must agree to meet the following from the first dose up to 1 month after the last dose of study treatment:

    • Not donate sperm
    • Either: be sexually abstinent in accordance with a patient's usual and preferred lifestyle (but agree to abide by the requirements below should their circumstances change) Or: use a condom with all sexual partners. If the partner is of the condom must be used with spermicide and a second highly effective form of contraception must also be used
  4. If female: either be:

    1. Of non-childbearing potential defined as being:

      • Either: (being spontaneously amenorrhoeic for at least 1 year with an appropriate clinical profile [e.g. age appropriate, history of vasomotor symptoms]
      • Or: permanently sterilised e.g. tubal occlusion, hysterectomy, bilateral oophorectomy, bilateral salpingectomy
    2. Of childbearing potential and agreeing to use a highly effective method of contraception until completion of the end of study visit.
  5. Have a 12-lead recording at screening and randomisation (pre-dose in Treatment Period 1) showing the following:

    • Heart rate between 45 and 90 beats per minute (bpm)
    • corrected for heart rate using Fridericia's formula (QTcF) ≤450 msec for males and ≤470 ms for females
    • QRS interval ≤120 msec
    • No abnormalities (as judged by the Investigator) including morphology (e.g. left bundle branch block, atrio-ventricular nodal dysfunction, ST segment abnormalities)
  6. Have a screening Holter report with a minimum of 18 hours recording that is able to be evaluated for rhythm analysis which shows no abnormality which indicates a significant impairment of patient safety or which may significantly impairs interpretation in the opinion of the Investigator including:

    • Significant arrhythmias including atrial flutter, atrial fibrillation, ventricular tachycardia
    • Any symptomatic arrhythmia (except isolated extra systoles)
    • Any sustained second or third degree heart block
  7. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser and HandiHaler® DPI correctly.
  8. (BMI) between 18 and 33 kg/m2 (inclusive) with a minimum weight of 45 kg.
  9. diagnosis: Patients with a diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (Celli and MacNee, 2004) with symptoms compatible with COPD for at least 1 year prior to screening.
  10. Post-bronchodilator (four puffs of salbutamol) spirometry at screening:

    • Post-bronchodilator (FEV1)/forced vital capacity (FVC) ratio of ≤0.70
    • Post-bronchodilator FEV1 ≥40 % and ≤80% of predicted normal
    • Demonstrates ≥150 mL increase from pre-bronchodilator FEV1
  11. Clinically stable COPD in the 4 weeks prior to screening and randomisation (pre-dose in Treatment Period 1).
  12. A chest X-ray (post-anterior) at screening, or in the 12 months prior to screening showing no abnormalities, which are both clinically significant and unrelated to COPD.
  13. Meet the concomitant medication restrictions and be expected to do so for the rest of the study.
  14. Smoking history of ≥10 pack years.
  15. Capable of withdrawing from long acting bronchodilators for the duration of the study, and short acting bronchodilators for 8 hours prior to spirometry.

Exclusion criteria

Exclusion Criteria:

  1. A history of life-threatening exacerbation including Intensive Care Unit admission and/or requiring intubation.
  2. COPD exacerbation requiring oral , or lower respiratory tract infection requiring antibiotics, in the 3 months prior to screening or randomisation (pre-dose in Treatment Period 1).
  3. A history of one or more hospitalisations for COPD in the 12 months prior to screening or randomisation (pre-dose in Treatment Period 1).
  4. Lactation (female patients only).
  5. Positive urine or serum pregnancy test at screening, or a positive urine pregnancy test prior to randomisation (female patients of only).
  6. Prior exposure to RPL554 or known to RPL554 or its components.
  7. Intolerance or hypersensitivity to tiotropium.
  8. Evidence of cor pulmonale.
  9. Other respiratory disorders: Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnoea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.
  10. Previous lung resection or lung reduction surgery.
  11. Use of oral COPD medications (e.g. oral steroids, theophylline and romifulast) in the 3 months prior to screening or randomisation (pre-dose in Treatment Period 1).
  12. History of, or reason to believe, a patient has drug or alcohol abuse within the past 3 years.
  13. Inability to perform technically acceptable spirometry or whole body plethysmography (at screening or randomisation [pre dose in Treatment Period 1])
  14. Received an experimental drug within 30 days or five half lives, whichever is longer.
  15. Patients with a history of chronic uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, haematological, urological, immunological, or ophthalmic diseases that the Investigator believes are .
  16. Documented cardiovascular disease: arrhythmias, angina, recent or suspected myocardial infarction, congestive heart failure, a history of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in the 3 months prior to screening or randomisation.
  17. Concurrent use of non-cardioselective oral beta-blockers.
  18. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to screening or randomisation (pre-dose in Treatment Period 1), or will not have fully recovered from surgery, or planned surgery through the end of the study.
  19. A disclosed history or one known to the Investigator, of significant non compliance in previous studies or with prescribed medications.
  20. Requires oxygen therapy, even on an occasional basis.
  21. Clinically significant prostatic hyperplasia (judged by the Investigator) or bladder-neck obstruction or with narrow-angle glaucoma.
  22. Any other reason that the Investigator considers makes the patient unsuitable to participate.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Lower Dose Nebulised Treatment

    1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days

    Drug: 1.5 mg RPL554 plus tiotropium

  • Experimental
    Higher Dose Nebulised Treatment

    6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days

    Drug: 6 mg RPL554 plus tiotropium

  • Placebo comparator
    Placebo

    Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days

    Drug: Placebo plus tiotropium

Interventions

06

What researchers measure

Primary outcomes

  1. Peak Forced Expired Volume in 1 Second (FEV1) on the Third Day of Dosing

    Peak forced expired volume in 1 second (FEV1) over 4 hours on the third day of dosing

    Time frame: Day 3

  2. Average FEV1 Over 12 Hours on the Third Day of Dosing

    Average FEV1 area under the curve (AUC) over 12 hours on the third day of dosing

    Time frame: Day 3

Secondary outcomes

  1. Peak FEV1 on Day 1

    Peak FEV1 over 4 hours on Day 1

    Time frame: Day 1

  2. Average FEV1 Over 12 Hours on Day 1

    Average FEV1 AUC over 12 hours on Day 1

    Time frame: Day 1

07

Results

Posted Jan 23, 2019

Participant flow

Participant flow — Overall Study
MilestonePlacebo Then Low Dose RPL554 Then High Dose RPL554Low Dose Dose RPL554 Then High Dose RPL554 Then PlaceboHigh Dose RPL554 Then Placebo Then Low Dose RPL554High Dose RPL554 Then Low Dose RPL554 Then PlaceboLow Dose RPL554 Then Placebo Then High Dose RPL554Placebo Then High Dose RPL554 Then Low Dose RPL554
Started556464
Completed446453
Not completed110011
Withdrew: Adverse event110001
Withdrew: Withdrawal by subject000010

Outcome measures

PrimaryPeak Forced Expired Volume in 1 Second (FEV1) on the Third Day of Dosing

Peak forced expired volume in 1 second (FEV1) over 4 hours on the third day of dosing

Time frame:
Day 3
Reported as:
Mean · Liters
Peak Forced Expired Volume in 1 Second (FEV1) on the Third Day of Dosing
LitersLower Dose Nebulised TreatmentHigher Dose Nebulised TreatmentPlacebo
Peak Forced Expired Volume in 1 Second (FEV1) on the Third Day of Dosing0.477 ± 0.16730.500 ± 0.21570.373 ± 0.1970
Statistical analysis
  • Lower Dose Nebulised Treatment vs Placebo · ANCOVA · p = 0.0022 · Ls means ratio: 1.05 · 95% CI 1.02 to 1.09
  • Higher Dose Nebulised Treatment vs Placebo · ANCOVA · p = <0.0001 · Ls means ratio: 1.09 · 95% CI 1.05 to 1.12
PrimaryAverage FEV1 Over 12 Hours on the Third Day of Dosing

Average FEV1 area under the curve (AUC) over 12 hours on the third day of dosing

Time frame:
Day 3
Reported as:
Mean · Liters*hour
Average FEV1 Over 12 Hours on the Third Day of Dosing
Liters*hourLower Dose Nebulised TreatmentHigher Dose Nebulised TreatmentPlacebo
Average FEV1 Over 12 Hours on the Third Day of Dosing3.804 ± 1.85123.967 ± 2.21343.197 ± 2.2826
Statistical analysis
  • Lower Dose Nebulised Treatment vs Placebo · ANCOVA · p = 0.0988 · Ls means ratio: 1.03 · 95% CI 0.99 to 1.06
  • Higher Dose Nebulised Treatment vs Placebo · ANCOVA · p = 0.0009 · Ls means ratio: 1.06 · 95% CI 1.02 to 1.09
SecondaryPeak FEV1 on Day 1

Peak FEV1 over 4 hours on Day 1

Time frame:
Day 1
Reported as:
Mean · Liters
Peak FEV1 on Day 1
LitersLower Dose Nebulised TreatmentHigher Dose Nebulised TreatmentPlacebo
Peak FEV1 on Day 10.383 ± 0.14480.432 ± 0.17200.337 ± 0.1854
Statistical analysis
  • Lower Dose Nebulised Treatment vs Placebo · ANCOVA · p = 0.2496 · Ls means ratio: 1.02 · 95% CI 0.98 to 1.06
  • Higher Dose Nebulised Treatment vs Placebo · ANCOVA · p = 0.0039 · Ls means ratio: 1.06 · 95% CI 1.02 to 1.1
SecondaryAverage FEV1 Over 12 Hours on Day 1

Average FEV1 AUC over 12 hours on Day 1

Time frame:
Day 1
Reported as:
Mean · Liters*hour
Average FEV1 Over 12 Hours on Day 1
Liters*hourLower Dose Nebulised TreatmentHigher Dose Nebulised TreatmentPlacebo
Average FEV1 Over 12 Hours on Day 13.058 ± 1.48513.094 ± 1.96242.510 ± 1.9381
Statistical analysis
  • Lower Dose Nebulised Treatment vs Placebo · ANCOVA · p = 0.1404 · Ls means ratio: 1.03 · 95% CI 0.99 to 1.06
  • Higher Dose Nebulised Treatment vs Placebo · ANCOVA · p = 0.0228 · Ls means ratio: 1.04 · 95% CI 1.01 to 1.08

Adverse events

Collected over From informed consent until the end of the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lower Dose Nebulised Treatment0/29 (0%)1/29 (3.4%)12/29 (41.4%)
Higher Dose Nebulised Treatment0/27 (0%)0/27 (0%)12/27 (44.4%)
Placebo0/28 (0%)0/28 (0%)12/28 (42.9%)
Most frequent serious events
Most frequent serious events
EventLower Dose Nebulised TreatmentHigher Dose Nebulised TreatmentPlacebo
PneumoniaInfections and infestations1/290/270/28
Most frequent other events
Showing 10 of 26
Most frequent other events
EventLower Dose Nebulised TreatmentHigher Dose Nebulised TreatmentPlacebo
HeadacheNervous system disorders2/295/273/28
Medical device site reactionGeneral disorders4/291/274/28
DyspnoeaRespiratory, thoracic and mediastinal disorders1/291/272/28
Chest discomfortGeneral disorders1/291/272/28
Catheter site bruiseGeneral disorders0/291/270/28
ChillsGeneral disorders0/291/270/28
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/291/270/28
Sputum increasedRespiratory, thoracic and mediastinal disorders0/291/270/28
Skin infectionInfections and infestations0/291/270/28
ArthralgiaMusculoskeletal and connective tissue disorders0/291/270/28

Baseline characteristics

All patients who received at least one dose of study treatment

Age, Continuous
Age, Continuous(years)Overall
Median64.5 (47 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female13
Male17
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White30
More than one race0
Unknown or Not Reported0
Percentage of predicted FEV1 post-bronchodilator
Percentage of predicted FEV1 post-bronchodilator(%)Overall
Mean60.1 ± 9.73
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018 Nov 1;52(5):1801074. doi: 10.1183/13993003.01074-2018. Print 2018 Nov. PubMed 30166326 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2017, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2017
First posted
Jan 23, 2017
Start
Jan 2017
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results first posted
Jan 23, 2019
Last update
Feb 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03028142
Lead sponsor
Verona Pharma plc
Responsible party
Sponsor
First posted
Jan 23, 2017
Start date
Jan 2017
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
Jan 23, 2019
Last update
Feb 27, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ensifentrine · Tiotropium

Start the discussion